Lexeo Therapeutics, Common Stock Today
| LXEO Stock | 7.83 0.50 6.82% |
Performance0 of 100
| Odds Of DistressLess than 21
|
Lexeo Therapeutics, is selling at 7.83 as of the 28th of November 2024; that is 6.82 percent up since the beginning of the trading day. The stock's open price was 7.33. Lexeo Therapeutics, has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Lexeo Therapeutics, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of November 2023 | Category Healthcare | Classification Health Care |
Lexeo Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 33.06 M outstanding shares of which 2.49 M shares are now shorted by private and institutional investors with about 6.55 trading days to cover. More on Lexeo Therapeutics, Common
Moving together with Lexeo Stock
| 0.7 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.84 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Lexeo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lexeo Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Nolan Townsend | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lexeo Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lexeo Therapeutics,'s financial leverage. It provides some insight into what part of Lexeo Therapeutics,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lexeo Therapeutics, Common (LXEO) is traded on NASDAQ Exchange in USA. It is located in 345 Park Avenue South, New York, NY, United States, 10010 and employs 69 people. Lexeo Therapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 254.24 M. Lexeo Therapeutics, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 33.06 M outstanding shares of which 2.49 M shares are now shorted by private and institutional investors with about 6.55 trading days to cover.
Lexeo Therapeutics, generates negative cash flow from operations
Check Lexeo Therapeutics, Probability Of Bankruptcy
Ownership AllocationLexeo Therapeutics, maintains a total of 33.06 Million outstanding shares. The majority of Lexeo Therapeutics, outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Lexeo Therapeutics, Common to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Lexeo Therapeutics,. Please pay attention to any change in the institutional holdings of Lexeo Therapeutics, as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Lexeo Ownership Details
Lexeo Therapeutics, Historical Income Statement
Lexeo Stock Against Markets
Lexeo Therapeutics, Corporate Management
| Ryan McHenry | VP Controller | Profile | |
| Jenny Robertson | Chief Officer | Profile | |
| Sandi MD | Senior Operations | Profile | |
| Jose Otero | Chief Officer | Profile | |
| Eric MD | Chief Research | Profile | |
| Jenny JD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.53) | Return On Assets (0.40) | Return On Equity (0.75) |
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.